Coronavirus-disease-2019-associated Stevens-Johnsons syndrome in a 15-year-old boy: a case report and review of the literature.
COVID-19
Pediatric
Stevens–Johnson syndrome
Toxic epidermal necrolysis
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
20
06
2024
accepted:
15
08
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Stevens-Johnson syndrome (SJS) is a life-threatening condition characterized by high fever and severe mucocutaneous lesions, often triggered by drugs or infection. During the coronavirus disease 2019 pandemic, there was a marked increase in Stevens-Johnson syndrome cases, but relatively few cases were reported in children. The present article reports a pediatric case of Stevens-Johnson syndrome due to coronavirus disease 2019 infection and provides a review of the most relevant literature. A previously healthy 15-year-old Han Chinese boy from China presented to the hospital with oral ulcers, conjunctival hyperemia, and widespread maculopapular rash. He had a history of fever 9 days prior and tested positive for coronavirus disease 2019 infection. Upon admission, his rash and mucosal lesions worsened, with the development of blisters on the fingertips of both hands, ocular pain, photophobia, and erosive lesions on the genital mucosa with exudation. He was diagnosed with Stevens-Johnson syndrome and received treatment with methylprednisolone, intravenous immunoglobulin, and dermatological and mucosal care. The patient's condition was managed, and the dosage of high-dose intravenous methylprednisolone was tapered down, followed by a transition to oral prednisolone. He was discharged without sequelae. We should be aware that coronavirus disease 2019 infection is associated with the development of Stevens-Johnson syndrome in children and may lead to a wide spectrum of dermatologic presentations. Although Stevens-Johnson syndrome is a relatively rare condition, given its potentially serious consequences, it is crucial to identify it as early as possible and to take appropriate preventive and therapeutic measures to reduce complications and improve the quality of life for patients.
Sections du résumé
BACKGROUND
BACKGROUND
Stevens-Johnson syndrome (SJS) is a life-threatening condition characterized by high fever and severe mucocutaneous lesions, often triggered by drugs or infection. During the coronavirus disease 2019 pandemic, there was a marked increase in Stevens-Johnson syndrome cases, but relatively few cases were reported in children. The present article reports a pediatric case of Stevens-Johnson syndrome due to coronavirus disease 2019 infection and provides a review of the most relevant literature.
CASE PRESENTATION
METHODS
A previously healthy 15-year-old Han Chinese boy from China presented to the hospital with oral ulcers, conjunctival hyperemia, and widespread maculopapular rash. He had a history of fever 9 days prior and tested positive for coronavirus disease 2019 infection. Upon admission, his rash and mucosal lesions worsened, with the development of blisters on the fingertips of both hands, ocular pain, photophobia, and erosive lesions on the genital mucosa with exudation. He was diagnosed with Stevens-Johnson syndrome and received treatment with methylprednisolone, intravenous immunoglobulin, and dermatological and mucosal care. The patient's condition was managed, and the dosage of high-dose intravenous methylprednisolone was tapered down, followed by a transition to oral prednisolone. He was discharged without sequelae.
CONCLUSION
CONCLUSIONS
We should be aware that coronavirus disease 2019 infection is associated with the development of Stevens-Johnson syndrome in children and may lead to a wide spectrum of dermatologic presentations. Although Stevens-Johnson syndrome is a relatively rare condition, given its potentially serious consequences, it is crucial to identify it as early as possible and to take appropriate preventive and therapeutic measures to reduce complications and improve the quality of life for patients.
Identifiants
pubmed: 39390502
doi: 10.1186/s13256-024-04842-3
pii: 10.1186/s13256-024-04842-3
doi:
Substances chimiques
Methylprednisolone
X4W7ZR7023
Immunoglobulins, Intravenous
0
Prednisolone
9PHQ9Y1OLM
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
493Informations de copyright
© 2024. The Author(s).
Références
Liotti L, Caimmi S, Bottau P, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3):52–60. https://doi.org/10.23750/abm.v90i3-S.8165 .
doi: 10.23750/abm.v90i3-S.8165
pubmed: 30830062
Wang L, Varghese S, Bassir F, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front Med (Lausanne). 2022;24(9): 949520. https://doi.org/10.3389/fmed.2022.949520 .
doi: 10.3389/fmed.2022.949520
Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.
doi: 10.1001/archderm.1993.01680220104023
pubmed: 8420497
DeBiasi RL, Song X, Delaney M, et al. Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region. J Pediatr. 2020;223:199-203.e1. https://doi.org/10.1016/j.jpeds.2020.05.007 .
doi: 10.1016/j.jpeds.2020.05.007
pubmed: 32405091
pmcid: 7217783
Yasuhara J, Kuno T, Takagi H, et al. Clinical characteristics of COVID-19 in children: a systematic review. Pediatr Pulmonol. 2020;55(10):2565–75. https://doi.org/10.1002/ppul.24991 .
doi: 10.1002/ppul.24991
pubmed: 32725955
Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol. 2023;64(1):e1–10. https://doi.org/10.1111/ajd.13958 .
doi: 10.1111/ajd.13958
pubmed: 36484649
Sorrell J, Anthony L, Rademaker A, et al. Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol. 2017;34(4):433–7. https://doi.org/10.1111/pde.13172 .
doi: 10.1111/pde.13172
pubmed: 28508417
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.
doi: 10.1016/j.jaad.2013.05.002
Jouhar L, Yahya M, Elsiddiq S. Toxic epidermal necrolysis associated with COVID-19 infection: a case report. Clin Case Rep. 2022;10: e05565.
doi: 10.1002/ccr3.5565
pubmed: 35310321
pmcid: 8918465
Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013;98:998–1003.
doi: 10.1136/archdischild-2013-303718
pubmed: 23873883
Rossi CM, Beretta FN, Traverso G, et al. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? Clin Mol Allergy. 2020;18:19. https://doi.org/10.1186/s12948-020-00133-6 .
doi: 10.1186/s12948-020-00133-6
pubmed: 33033459
pmcid: 7537980
Chang HC, Wang TJ, Lin MH, et al. A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biomedicines. 2022;10(9):2105. https://doi.org/10.3390/biomedicines10092105 .
doi: 10.3390/biomedicines10092105
pubmed: 36140207
pmcid: 9495335
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.
doi: 10.1080/01926230701320337
pubmed: 17562483
pmcid: 2117903
Stur K, Karlhofer FM, Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol. 2007;127(4):802–7. https://doi.org/10.1038/sj.jid.5700648 .
doi: 10.1038/sj.jid.5700648
pubmed: 17139262
Su SC, Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins (Basel). 2014;6(1):194–210. https://doi.org/10.3390/toxins6010194 .
doi: 10.3390/toxins6010194
pubmed: 24394640
pmcid: 3920257
Saeed HN, Chodosh J. Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis. Semin Ophthalmol. 2016;31(1–2):85–90. https://doi.org/10.3109/08820538.2015.1115255 .
doi: 10.3109/08820538.2015.1115255
pubmed: 26959133
Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50. https://doi.org/10.1038/nm.1884 .
doi: 10.1038/nm.1884
pubmed: 19029983
Stanley EA, Zhang L, O’Hara J, et al. The seven-fold rise in incidence of Stevens-Johnson syndrome & toxic epidermal necrolysis: associations with COVID-19 and the vaccine. Burns. 2024;50(1):87–92. https://doi.org/10.1016/j.burns.2023.06.016 .
doi: 10.1016/j.burns.2023.06.016
pubmed: 37730480
Varol F, Can YY, Sahin E, et al. The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID-19. J Clin Apher. 2022;37:516–21. https://doi.org/10.1002/jca.21997 .
doi: 10.1002/jca.21997
pubmed: 35792366
pmcid: 9350357
Metbulut AP, Özkaya Parlakay A, Bayhan Gİ, et al. Evaluation of cutaneous symptoms in children infected with COVID-19. Pediatr Allergy Immunol. 2021;32(5):1120–5. https://doi.org/10.1111/pai.13467 .
doi: 10.1111/pai.13467
pubmed: 33555642
pmcid: 8013869
Haraguchi S, Tsubokura S, Ozasa K, et al. Pediatric Stevens-Johnson syndrome associated with severe acute respiratory syndrome coronavirus 2 infection. Pediatr Int. 2022;64(1): e15366. https://doi.org/10.1111/ped.15366 .
doi: 10.1111/ped.15366
pubmed: 36165959
Sljivic S, Pogson K, Williams FN, et al. COVID-induced toxic epidermal necrolysis in a 4-year-old female: a case report and literature review. Int J Burns Trauma. 2022;12(5):204–9.
pubmed: 36420101
pmcid: 9677226
Parlakay AO, Ozcan S, Karaatmaca B, et al. COVID-19 presenting like Steven Johnson Syndrome in a pediatric patient. Authorea preprints. 2020.
Aulakh S, Arora R, Sarangal R, et al. Increased predisposition of SJS TEN in COVID-19 patients, presenting as post COVID complication: report of two cases. Indian Dermatol Online J. 2022;13(2):237–9. https://doi.org/10.4103/idoj.idoj_510_21 .
doi: 10.4103/idoj.idoj_510_21
pubmed: 35287406
pmcid: 8917493
Tanaka A, Isei M, Kikuzawa C, et al. Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARSCoV-2 viral RNA. J Dermatol. 2021;48(3):e144–5. https://doi.org/10.1111/1346-8138.15753 .
doi: 10.1111/1346-8138.15753
pubmed: 33439527
pmcid: 8014636
Emadi S, Hamzelou S, Saffarian Z, et al. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: a case report. Dermatol Ther. 2021;34(1): e14656. https://doi.org/10.1111/dth.14656 .
doi: 10.1111/dth.14656
pubmed: 33301196
Bulat V, Likic R, Pondeljak N. Pholcodine-induced Stevens-Johnson syndrome in a patient with COVID-19. Postgrad Med J. 2022;98(1161):499–500. https://doi.org/10.1136/postgradmedj-2021-139892 .
doi: 10.1136/postgradmedj-2021-139892
pubmed: 33879549
Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020. https://doi.org/10.12688/f1000research.24748.1 .
doi: 10.12688/f1000research.24748.1
pubmed: 32595945
pmcid: 7308994